F Ossendorp
Overview
Explore the profile of F Ossendorp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
1421
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Da Silva C, Camps M, Li T, Chan A, Ossendorp F, Cruz L
Biomaterials
. 2019 Aug;
220:119417.
PMID: 31419588
To improve the efficacy of cancer vaccines we aimed to modulate the suppressive tumor microenvironment. In this study, the potential of intratumoral immune modulation with poly (I:C), Resiquimod (R848) and...
2.
Silva A, Soema P, Slutter B, Ossendorp F, Jiskoot W
Hum Vaccin Immunother
. 2016 Jan;
12(4):1056-69.
PMID: 26752261
Among the emerging subunit vaccines are recombinant protein- and synthetic peptide-based vaccine formulations. However, proteins and peptides have a low intrinsic immunogenicity. A common strategy to overcome this is to...
3.
Rosendahl Huber S, Camps M, Jacobi R, Mouthaan J, van Dijken H, van Beek J, et al.
PLoS One
. 2015 Jun;
10(6):e0127969.
PMID: 26046664
Currently licensed influenza vaccines mainly induce antibodies against highly variable epitopes. Due to antigenic drift, protection is subtype or strain-specific and regular vaccine updates are required. In case of antigenic...
4.
Silva A, Rosalia R, Varypataki E, Sibuea S, Ossendorp F, Jiskoot W
Vaccine
. 2015 Jan;
33(7):847-54.
PMID: 25576216
Poly(lactic-co-glycolic acid) (PLGA) particles have been extensively studied as biodegradable delivery system to improve the potency and safety of protein-based vaccines. In this study we analyzed how the size of...
5.
Silva A, Rosalia R, Sazak A, Carstens M, Ossendorp F, Oostendorp J, et al.
Eur J Pharm Biopharm
. 2012 Dec;
83(3):338-45.
PMID: 23201055
Overlapping synthetic long peptides (SLPs) hold great promise for immunotherapy of cancer. Poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) are being developed as delivery systems to improve the potency of peptide-based therapeutic...
6.
Unger W, Pinkse G, Mulder-van der Kracht S, van der Slik A, Kester M, Ossendorp F, et al.
Ann N Y Acad Sci
. 2007 Mar;
1103:192-5.
PMID: 17376840
Type 1 diabetes (T1D) is a multifactorial disease characterized by the infiltration and subsequent destruction of the pancreatic insulin-producing beta cells by autoreactive T cells. CD8(+) T cells play an...
7.
Kessler J, Bres-Vloemans S, van Veelen P, de Ru A, Huijbers I, Camps M, et al.
Leukemia
. 2006 Aug;
20(10):1738-50.
PMID: 16932347
For immunotherapy of residual disease in patients with Philadelphia-positive leukemias, the BCR-ABL fusion regions are attractive disease-specific T-cell targets. We analyzed these regions for the prevalence of cytotoxic T lymphocyte...
8.
Charo J, Geluk A, Sundback M, Mirzai B, Diehl A, Malmberg K, et al.
Eur J Immunol
. 2001 Dec;
31(12):3602-11.
PMID: 11745380
Bacterial antigens recognized by CD8(+) T cells in the context of MHC class I are thought to play a crucial role in protection against pathogenic intracellular bacteria. Here, we demonstrate...
9.
Kleijmeer M, Ramm G, Schuurhuis D, Griffith J, Rescigno M, Ricciardi-Castagnoli P, et al.
J Cell Biol
. 2001 Oct;
155(1):53-63.
PMID: 11581285
Immature dendritic cells (DCs) sample their environment for antigens and after stimulation present peptide associated with major histocompatibility complex class II (MHC II) to naive T cells. We have studied...
10.
Medema J, Schuurhuis D, Rea D, van Tongeren J, de Jong J, Bres S, et al.
J Exp Med
. 2001 Sep;
194(5):657-67.
PMID: 11535633
Dendritic cells (DCs) play a central role in the immune system as they drive activation of T lymphocytes by cognate interactions. However, as DCs express high levels of major histocompatibility...